The global TNF inhibitors market is gaining momentum as the prevalence of autoimmune and chronic inflammatory diseases continues to increase worldwide. Rheumatoid arthritis (RA), psoriasis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and other immune-mediated disorders represent major areas of clinical demand for tumor necrosis factor (TNF) inhibitors. These biologic...